News

Posts are organized into categories for ease of navigation:

  • Database release

    Added entries:

    • (FDA) ABL1 p.T315I and sensitivity to ponatinib for patients with acute lymphoid leukemia.
    • (FDA) ABL1 p.T315I and sensitivity to ponatinib for patients with chronic myeloid leukemia.
    • (FDA) BCR::ABL1 and sensitivity to ponatinib in combination with chemotherapy for patients with acute lymphoid leukemia.
    • (FDA) BCR::ABL1 and sensitivity to ponatinib for patients with acute lymphoid leukemia.
    Continue reading
  • Database release

    Added entries:

    • (FDA) ALK fusions and sensitivity to crizotinib for patients with anaplastic large cell lymphoma.
    • (FDA) EGFR exon 20 insertions and sensitivity to amivantamab-vmjw in combination with carboplatin and pemetrexed for patients with non-small cell lung cancer.
    • (FDA) EGFR exon 19 deletions or p.L858R and sensitivity to osimertinib in combination with cisplatin and pemetrexed for patients with locally advanced or metastatic non-small cell lung cancer.
    • (FDA) EGFR exon 19 deletions or p.L858R and sensitivity to osimertinib for patients with metastatic non-small cell lung cancer.
    • (FDA) MET exon 14 splice site and deletion variants (exon 14 skipping) and sensitivity to tepotinib for patients with metastatic non-small cell lung cancer.
    Continue reading
  • Database release

    Added entries:

    • (FDA) BRAF p.V600E/K and sensitivity to vemurafenib for patients with Erdheim-Chester disease.
    Continue reading
  • Database release

    Added entries:

    • (FDA) ERBB2 amplification and sensitivity to neratinib in combination with capecitabine for patients with breast cancer.
    Continue reading
  • Algorithm release 0.5.0

    This release utilizes the v.2023-11-09 release of the underlying MOAlmanac database and incorporates changes from three pull requests: #15: Added AIP to hereditary cancers gene list, #16: Update db nov 2023, and #17: Revise handling of COSMIC mutational signatures.

    Continue reading